NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Estimated value
—
goods
Awarded value
—
Suppliers
24
6 SME
Lots
2
0 awarded
Published
29 Jul 2025
Total lots
2
Awarded
0
2 pending
Estimated total
£2.9bn
Awarded total
—
Lot 1cancelled
Lot 1 - CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East
Estimated
£2.8bn
Start
31 Aug 2025
End
31 Aug 2027
Estimated
£2.8bn
CPV
33600000
No suppliers awarded yet for this lot.
Lot 2cancelled
Lot 2 - CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE
Estimated
£26.4m
Start
31 Aug 2025
End
31 Aug 2027
Estimated
£26.4m
CPV
33600000
No suppliers awarded yet for this lot.